Bispecific Subcutaneous Formulation Breaks Decade-Long Therapeutic Drought in Advanced HNSCC
On November 5, 2026, the United States Food and Drug Administration (FDA) formally granted accelerated approval to Johnson & Johnson's Rybrevant Faspro (subcutaneous amivantamab and hyaluronidase-lpuj, supplied as 160 mg and 2,000 units per mL) as a single-agent therapeutic for adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The regulatory indication applies specifically to individuals whose malignant disease has progressed on or after prior platinum-based chemotherapy and an anti-PD-(L)1 programmed death receptor inhibitor.
The landmark regulatory decision resolves a protracted decade-long therapeutic stagnation in post-platinum advanced oncology. Head and neck squamous cell carcinoma represents an aggressive, structurally debilitating malignancy that severely compromises fundamental physiological functions, including speech articulation, mastication, swallowing, and airway patency. Historically, oncology patients who experience systemic disease progression following frontline chemotherapy and checkpoint immunotherapies confront dismal prognostic outcomes, with subsequent salvage regimens yielding objective response rates hovering near or below 20 percent.
OrigAMI-4 Clinical Trial Demonstrates 42% Overall Response Rate with 15% Complete Responses
The FDA's accelerated approval pathway was substantiated by clinical response duration and tumor reduction data generated within the multi-cohort Phase 1b/2 OrigAMI-4 trial. In the clinical study evaluating heavily pretreated patients, Rybrevant Faspro demonstrated unprecedented dual-targeting anti-tumor efficacy. Evaluated by blinded independent central review, the overall response rate (ORR) reached 42 percent across the primary efficacy cohort, with 15 percent of participating patients achieving complete radiographic disappearance of measurable target lesions.
The authorization represents the initial global regulatory approval for the co-formulated subcutaneous bispecific antibody outside of its established indications in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. By simultaneously binding to EGFR and mesenchymal-epithelial transition factor (MET) receptors while recruiting immune effector cells, the co-formulation delivers targeted therapeutic suppression against compensatory oncogenic resistance pathways. Johnson & Johnson executive leadership confirmed that commercial distribution channels across United States cancer centers will mobilize immediately, while confirmatory randomized Phase 3 trials continue to verify durable overall survival benefits.
Landmark First Regulatory Approval Outside Non-Small Cell Lung Cancer Setting
Oncology researchers emphasized that subcutaneous administration significantly reduces clinical chair time compared to lengthy intravenous infusions. The incorporation of recombinant human hyaluronidase facilitates rapid subcutaneous dispersion, allowing ambulatory oncology clinics to administer the targeted biologic in minutes, enhancing overall patient convenience and treatment adherence across regional healthcare systems.
The accelerated approval rests on the phase 2 OrigAMI-4 trial, where the objective response rate reached 42 percent and 15 percent of patients had a complete response.